Skip to main content

Table 3 Rate Differences (events/10.000 person-years [95% confidence interval]) for all-cause mortality and CVD endpoints after a 5-year follow-up by HbA1c categories

From: Mortality and cardiovascular disease burden of uncontrolled diabetes in a registry-based cohort: the ESCARVAL-risk study

 

C / NC

Total mortality

C / NC

CHD hospitalization

C / NC

Stroke hospitalization

eGFR

 

Model 1

Model 2

 

Model 1

Model 2

 

Model 1

Model 2

<  6

116 / 4188

Ref.

Ref.

169 / 4135

Ref.

Ref.

161 / 4143

Ref.

Ref.

6–6.5

80 / 3693

−13.26

(−32.40, 5.88)

−11.44

(−30.75, 7.86)

154 / 3619

11.71

(−13.33, 36.74)

11.41

(−13.57, 36.39)

166 / 3607

24.14

(−1.22, 49.50)

22.30

(−3.16, 47.77)

6.5–7

72 / 3267

− 12.42

(− 32.08, 7.23)

−6.93

(−26.87, 13.02)

155 / 3184

28.06

(−0.06, 56.17)

25.04

(− 3.36, 53.45)

126 / 3213

3.64

(−22.45, 29.74)

0.10

(−26.13, 26.32)

7–7.5

60 / 2339

−5.34

(−27.81, 17.13)

4.24

(−18.73, 27.20)

123 / 2276

39.60

(7.54, 71.66)

37.34

(4.92, 69.76)

90 / 2309

− 0.06

(− 27.92, 27.81)

−4.88

(− 33.34, 23.57)

> = 7

171 / 5154

28.26

(9.17, 47.36)

34.22

(14.55, 53.90)

311 / 5014

72.24

(46.83, 97.64)

70.26

(44.43, 96.09)

243 / 5082

42.74

(18.58, 66.90)

35.15

(10.51, 59.79)

P-trend

 

0.001

< 0.001

 

< 0.001

< 0.001

 

0.007

0.044

  1. Model 1 is adjusted for age and sex. Model 2 is further adjusted smoking status (never, former, current), obesity (no, yes), hypertension (no, yes), chronic kidney disease (no, yes), HDL cholesterol ≤40 for men and ≤ 50 for women (no, yes), LDL ≥ 130 mg/dL (no, yes), anti-hypertensive medication (no, yes), glucose lowering medication (no, yes), lipid lowering medication (no, yes)